Full Text View
Tabular View
No Study Results Posted
Related Studies
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
This study is currently recruiting participants.
Verified by Department of Veterans Affairs, February 2009
First Received: February 6, 2007   Last Updated: February 26, 2009   History of Changes
Sponsored by: Department of Veterans Affairs
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00432601
  Purpose

The purpose of this study is to test different methods for communicating information about prostate cancer treatment to men. We are studying how best to present information so men can make good decisions about what prostate cancer treatment to undergo.


Condition Intervention
Prostate Cancer
Behavioral: type of decision aid

MedlinePlus related topics: Cancer Prostate Cancer
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study
Official Title: Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • knowledge, risk perception, decision making, patient-physician communication [ Time Frame: Prebiopsy appointment (Time 1); Diagnosis visit (Time 2); 7-10 Days After Diagnosis visit (Time 3) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • satisfaction with decision aid, anxiety [ Time Frame: Anxiety:Prebiopsy appointment (Time 1); Diagnosis visit (Time 2); 7-10 Days After Diagnosis visit (Time 3). Satisfaction: 7-10 Days After Diagnosis visit (Time 3) ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: August 2008
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Patients will receive Michigan Cancer Consortium decision aid.
Behavioral: type of decision aid
We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
2: Active Comparator
Patients will receive National Comprehensive Cancer Network decision aid.
Behavioral: type of decision aid
We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.

Detailed Description:

Background:

Background/Rationale: Prostate cancer is the second leading cause of related death among men in the United States, and accounts for 33% of all cancers diagnosed in men. Furthermore, approximately one in six men will be diagnosed with prostate cancer in their lifetime. Thus, 17% of male Veterans will be asked to make a decision about the treatment of their prostate cancer. The burden of this disease is further magnified when one considers that most patients, once diagnosed, will live for years following their diagnosis and with any adverse effects of therapy. Given that there have been no clinical trails which have proven that any prostate cancer treatment produces an increased likelihood of survival; men are asked to actively participate in decisions about what treatment to undergo. Previous research has revealed that men are often uninformed about their prostate cancer, particularly African American men and men with lower educational attainment. Thus, it is critical to develop and test decision aids that can help all men (especially men with low literacy skills) make an informed decision. However, this study will go beyond most decision aid research which has focused primarily on knowledge, treatment choice, and decisional conflict and will examine the impact of a decision aid on patient-physician interactions. Furthermore, invirtually no research has tested the use of decision aids with low literacy patients, as this study will.

Objectives:

Objective(s): To test the impact of a plain language decision aid (i.e., a low reading level) on prostate cancer patient's decision making experience and in their interactions with their physician and the VA health system. This study will also test if there are differences in receipt of active treatment between men with low vs. high literacy skills.

Methods:

Methods: The proposed study will be a randomized controlled trial. Men who are undergoing a prostate biopsy to will be recruited at the time of biopsy and those patients with a positive biopsy result will be interviewed at 3 time points: Baseline (at pre-biopsy appointment), at physician visit (diagnosis), and 10 days following physician visit (phone survey). Also, the treatment discussion between patients and their physician will be taped and coded.

Major characteristics: All men, without a prior history of prostate cancer, undergoing a prostate biopsy will be screened for eligibility and enrolled by the study coordinator before they undergo a prostate biopsy. Additional inclusion criteria include ability to speak English, provide informed consent, and having a 5 year or greater expected survival as determined by their physician. Physicians can refuse to allow a patient participate in the study at the time of biopsy. 500 men will be recruited at 4 VAs: Ann Arbor, Pittsburgh, San Francisco and Durham. Men will be randomized to either receive one of two types of decision aids.

Major variables and source(s) of data: All survey data will come from either face-to-face or phone interviews. Survey variables testing the impact of the decision aid will include: 1) treatment decision, 2) involvement in the decision making process, 3) knowledge of risks and benefits, 4) self-efficacy for decision making, and 5) satisfaction with decision aid.

Status:

Recruitment began 9/2/08.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Must be undergoing a prostate cancer biopsy at Ann Arbor, Durham, San Francisco, or Pittsburgh VAs

Exclusion Criteria:

Prior history of prostate cancer

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00432601

Contacts
Contact: Julie Parow, BA (734) 936-4175 jparow@Umich.edu

Locations
United States, California
VA Medical Center Not yet recruiting
San Francisco, California, United States, 94121
Contact: Julie Parow, BA     734-936-4175     jparow@Umich.edu    
Sub-Investigator: Sara J. Knight, PhD            
Sub-Investigator: Christopher Kane, MD            
United States, Michigan
VA Ann Arbor Healthcare System Recruiting
Ann Arbor, Michigan, United States, 48113-0170
Contact: Angela Fagerlin, PhD MA         fagerlin@umich.edu    
Contact: Janet G Adams-Watson, MHSA BA     (734) 845-3604     jan.adams-watson@va.gov    
Principal Investigator: Angela Fagerlin, PhD MA            
Sub-Investigator: Peter A. Ubel, MD            
Sub-Investigator: Khaled Hafez, MBBS            
United States, North Carolina
VA Medical Center, Durham Not yet recruiting
Durham, North Carolina, United States, 27705
Contact: Julie Parow, BA     734-936-4175     jparow@Umich.edu    
Sub-Investigator: Stewart C. Alexander, BA MA PhD            
Sub-Investigator: James A. Tulsky, MD            
United States, Pennsylvania
Center for Health Equity Research and Promotion Not yet recruiting
Pittsburgh, Pennsylvania, United States, 15206
Contact: Julie Parow, BA     734-936-4175     jparow@Umich.edu    
Sub-Investigator: Bruce S. Ling, MD MPH            
Sponsors and Collaborators
Investigators
Principal Investigator: Angela Fagerlin, PhD MA VA Ann Arbor Healthcare System
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs ( Fagerlin, Angela - Principal Investigator )
Study ID Numbers: IIR 05-283
Study First Received: February 6, 2007
Last Updated: February 26, 2009
ClinicalTrials.gov Identifier: NCT00432601     History of Changes
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
decision aid
prostate cancer
patient-physician communication
decision making
literacy

Study placed in the following topic categories:
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on May 06, 2009